Mylan, Orion sign settlement, license agreement for generic version of STALEVO - News-Medical.net
Mylan, Orion sign settlement, license agreement for generic version of STALEVONews-Medical.
SERVICIO PÚBLICO Paciente con Parkinson necesita Stalevo y Madopar - Noticia al Dia
Noticia al DiaSERVICIO PÚBLICO Paciente con Parkinson necesita Stalevo y MadoparNoticia al DiaEl profesor José Ríos del Colegio la Merced requiere con caracter de urgencia los siguientes medicamentos Stalevo 50 o 100 MG, Madopar de 200 MG, Sinemet 50/200 MG, Sentralina 50 MG para tratar el Mal de Parkinson.
Research and Markets: Orion's Stalevo/Comtan (Parkinson's Disease) Forecast and Market Analysis to 2022 - Business Wire (press release)
Research and Markets: Orion's Stalevo/Comtan (Parkinson's Disease) Forecast and Market Analysis to 2022Business Wire (press release)Comtan (entacapone) was developed by Orion for Parkinson's disease patients who experience end-of-dose wearing-off.
FDA Review Finds No Increased Cardiovascular Risk With Entacapone in Parkinson's - Medscape
MedscapeFDA Review Finds No Increased Cardiovascular Risk With Entacapone in Parkinson'sMedscapeIn August 2010, the FDA announced that it would review clinical trial data suggesting that patients with PD taking Stalevo may be at a higher risk for cardiovascular events compared with those taking a combination of carbidopa and levodopa (Sinemet .
NEW L-DOPA PRODUCT EXCEEDS THE EFFECT OF STALEVO - Parkinson's Disease News
Parkinson's Disease NewsNEW L-DOPA PRODUCT EXCEEDS THE EFFECT OF STALEVOParkinson's Disease NewsA new L-dopa product, which is presently called ODM-101, significantly decreased daily OFF-time without increasing ON-time with troublesome dyskinesias when compared to Stalevo, which is a standard medication in advanced Parkinson's Disease when .